--- title: "Inside the 2026 Buyback Spree: Tencent and Want Want Double Down" type: "News" locale: "en" url: "https://longbridge.com/en/news/297634151.md" description: "As market dynamics shift in 2026, tech and consumer giants Tencent and Want Want are executing aggressive share repurchases. Concurrently, AI-driven biopharma firms are hitting unprecedented commercial and clinical milestones." datetime: "2026-09-01T10:12:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297634151.md) - [en](https://longbridge.com/en/news/297634151.md) - [zh-HK](https://longbridge.com/zh-HK/news/297634151.md) generator: "portal-rs" --- # Inside the 2026 Buyback Spree: Tencent and Want Want Double Down Corporate confidence is making a major statement in 2026, and it is written entirely in share repurchases. While the broader market searches for direction, tech and consumer heavyweights are opening their wallets to buy back their own stock in substantial volumes. Leading the charge is 腾讯控股（80700.HK）. The technology behemoth recently executed another massive buyback, scooping up shares worth approximately HKD 100 million in early September 2026 and signaling a relentless commitment to shareholder returns. Not to be outdone in the consumer sector, 中国旺旺（151.HK）has been on a 26-day repurchase streak since late July. Having already poured over HKD 217 million into buybacks this summer, the snack and beverage maker is aggressively capitalizing on its valuation following a recent dividend payout. Beyond capital engineering, actual business fundamentals are showing pockets of aggressive growth, particularly in the AI-biopharma nexus. 剂泰科技（7666.HK）, fresh off its May 2026 debut, is already turning heads. Its inaugural mid-year report revealed that first-half revenue blew past its entire prior-year total, proving its AI-for-Science platform is gaining serious commercial traction. Similarly, 乐普生物（2157.HK）is reaping the rewards of its commercialization strategy. With sales from its core products doubling compared to the same period in 2025, and its crucial ADC candidate hitting primary endpoints in global Phase III trials, the company has firmly established continuous profitability. Here is what else is happening across the market: - **Infrastructure and Retail Gains:** Heavy equipment manufacturer 哈尔滨电气（1133.HK）delivered a massive 63% surge in first-half net profit, fueled by record-breaking new contracts in the nuclear and coal power sectors. On the consumer front, convenience operator 利亞零售（831.HK）posted steady single-digit growth in both turnover and bottom-line profit. - **Struggles and Scrutiny:** It is not all green. Watch retailer 亨得利（3389.HK）swung to a net loss of RMB 31.8 million in the first half amid internal boardroom turbulence. Meanwhile, property manager 世茂服务（1617.HK）faced a public reprimand from the Shanghai Stock Exchange over disclosure violations, overshadowing its RMB 3.35 billion interim revenue. - **Quiet Corners:** Operators like 新高教集团（825.HK）, 中国 A8 新媒体（290.HK）, and 南方锰业 have kept a low profile this season with no major mid-year catalysts announced yet. ### Related Stocks - [00151.HK](https://longbridge.com/en/quote/00151.HK.md) - [00825.HK](https://longbridge.com/en/quote/00825.HK.md) - [07666.HK](https://longbridge.com/en/quote/07666.HK.md) - [00831.HK](https://longbridge.com/en/quote/00831.HK.md) - [01133.HK](https://longbridge.com/en/quote/01133.HK.md) - [80700.HK](https://longbridge.com/en/quote/80700.HK.md) - [03389.HK](https://longbridge.com/en/quote/03389.HK.md) - [00290.HK](https://longbridge.com/en/quote/00290.HK.md) - [01617.HK](https://longbridge.com/en/quote/01617.HK.md) - [02157.HK](https://longbridge.com/en/quote/02157.HK.md) ## Related News & Research - [Tencent Raises US$1.8 Billion and CNY26 Billion in Long-Dated Note Offering](https://longbridge.com/en/news/302623170.md) - [DeepSeek wrapping up $15 billion fundraising to fuel AI race](https://longbridge.com/en/news/302642673.md) - [Linmon Media Strikes Tencent Framework Deal for Game and Derivative Rights](https://longbridge.com/en/news/302854831.md) - [Nvidia May Be Helping Finance Oracle's AI Data Centers, TD Cowen Says](https://longbridge.com/en/news/302450831.md) - [METiS TechBio signs $1.1B AI drug-delivery deal with Eli Lilly](https://longbridge.com/en/news/302360581.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**